Spruce Biosciences Q1 FY26 net loss narrows to $12.27 million; R&D expenses fall to $7.58 million

• Spruce Biosciences posted a first-quarter net loss of $12.27 million, narrowing from $14.04 million a year earlier; loss per share improved to $8.94 from $23.95.
• R&D expense fell to $7.58 million from $10.84 million, due to $5.7 million of one-time product acquisition costs tied to SPR202 and $1.9 million from discontinuing the tildacerfont congenital adrenal hyperplasia program.
• G&A expense rose to $4.41 million from $3.66 million, while total operating expense declined to $11.99 million from $14.49 million.
• Cash and cash equivalents totaled $54.08 million at March 31, rising from $48.91 million at year-end; cash was about $107.3 million as of April 30 following a $69 million public offering and a $50 million term loan facility with Avenue Capital.
• Management reiterated plans to submit a BLA for TA-ERT in MPS IIIB in fourth-quarter 2026, citing continued progress on manufacturing readiness, regulatory interactions, and commercial planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260513782733) on May 13, 2026, and is solely responsible for the information contained therein.